- Login
- Register & Subscribe
- Sprache: EN FR DE
Finance, Grants, Deals
J&J to acquire prostate cancer drug
Monday 17 June 2013
Johnson & Johnson Inc is set to pay up to $1 billion to acquire privately-held Aragon Pharmaceuticals Inc of the US which has a product in Phase 2 development for castration resistant prostate cancer. The upfront payment is $650 million.
Location
United States
Index Ventures backs novel anticoagulant
Monday 17 June 2013
Index Ventures is launching a virtual, single-product company that is developing a monoclonal antibody with the potential, it says, to prevent heart attack and stroke without causing bleeding. The antibody targets the clotting enzyme thrombin. The funding was announced on 17 June.
Location
United Kingdom
AstraZeneca to acquire respiratory company
Monday 10 June 2013
AstraZeneca Plc is to pay up to $1.15 billion to acquire privately-held Pearl Therapeutics Inc of the US which has a Phase 3 product in development for chronic obstructive pulmonary disease, as well as inhaler and formulation technology with potential application in future combination products.
Location
United Kingdom
Cardio3 BioSciences plans IPO
Tuesday 4 June 2013
Cardio3 BioSciences SA of Belgium has announced plans to raise new funds through an initial public offering of its shares on the NYSE Euronext exchanges in both Brussels and Paris. The company has a cell therapy for heart repair in Phase 3.
Location
Belgium
MorphoSys outlicenses antibody to GSK
Monday 3 June 2013
MorphoSys AG has successfully outlicensed its first proprietary antibody, MOR103 for rheumatoid arthritis, to GlaxoSmithKline Plc in a deal potentially valued at €445.5 million. The German company is set to receive an upfront payment of €22.5 million.
Location
Germany
Horizon Discovery completes Series C round
Monday 3 June 2013
Horizon Discovery Ltd has announced the final closing of its Series C funding round with share placements valued at £6.9 million. The total sum raised in the round is £18.2 million which will be used to advance its research tools including cell lines.
Location
United Kingdom
GSK acquires Swiss vaccine company
Wednesday 29 May 2013
GlaxoSmithKline Plc has paid €250 million in cash for the Switzerland-based vaccine company, Okairos AG, which has developed technology applicable to both prophylactic and therapeutic vaccine products.
Location
United Kingdom
Prosensa registers for US IPO
Wednesday 29 May 2013
Prosensa Holding BV of the Netherlands, which is developing an antisense oligonucleotide for Duchenne muscular dystrophy, has made a filing with the US Securities and Exchange Commission for a proposed initial public share offering.
Location
Netherlands
Austrian antisense developer gets funding
Wednesday 29 May 2013
Ugichem GmbH of Austria, which has developed a new antisense drug technology platform, has raised €2.25 million from public and private investors to advance preclinical drug candidates for immune-mediated inflammatory diseases.
Location
Austria
AstraZeneca to pay up to $443 million for Omthera
Tuesday 28 May 2013
AstraZeneca Plc is to pay up to $443 million to acquire Omthera Pharmaceuticals Inc of Princeton, New Jersey, a five-year-old company with a single product – a late stage omega-3 free fatty acid composition to treat hypertriglyceridaemia.
Location
United Kingdom
Select a News Category
Recent Appointments
Steffen Thirstrup joins NDA Group
Monday June 10 2013
Tarquin Bennett-Coles joins Odgers Berndtson
Monday June 10 2013
Sandy Eisen becomes non-executive director at Phosphate Therapeutics
Thursday June 6 2013
Eric-Paul Paques to chair Grünenthal
Thursday June 6 2013
Charles DeCarli joins advisory board at DiaGenic
Thursday June 6 2013